X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NOVARTIS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NOVARTIS DIVIS LABORATORIES/
NOVARTIS
 
P/E (TTM) x 32.5 322.3 10.1% View Chart
P/BV x 5.8 35.7 16.3% View Chart
Dividend Yield % 0.9 1.3 66.6%  

Financials

 DIVIS LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
NOVARTIS
Mar-18
DIVIS LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,222758 161.2%   
Low Rs784579 135.4%   
Sales per share (Unadj.) Rs153.1228.4 67.0%  
Earnings per share (Unadj.) Rs39.931.7 125.9%  
Cash flow per share (Unadj.) Rs44.632.8 136.1%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.01.5 66.7%  
Book value per share (Unadj.) Rs201.8297.1 67.9%  
Shares outstanding (eoy) m265.4724.69 1,075.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.62.9 223.8%   
Avg P/E ratio x25.121.1 119.2%  
P/CF ratio (eoy) x22.520.4 110.2%  
Price / Book Value ratio x5.02.2 220.9%  
Dividend payout %25.031.5 79.5%   
Avg Mkt Cap Rs m266,26616,505 1,613.2%   
No. of employees `0009.70.7 1,457.3%   
Total wages/salary Rs m4,6871,445 324.3%   
Avg. sales/employee Rs Th4,175.08,441.3 49.5%   
Avg. wages/employee Rs Th481.52,163.6 22.3%   
Avg. net profit/employee Rs Th1,089.31,173.1 92.9%   
INCOME DATA
Net Sales Rs m40,6435,639 720.8%  
Other income Rs m7491,718 43.6%   
Total revenues Rs m41,3927,357 562.6%   
Gross profit Rs m14,460-63 -23,136.6%  
Depreciation Rs m1,23325 4,874.7%   
Interest Rs m2355 40.9%   
Profit before tax Rs m13,9531,575 885.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349792 423.1%   
Profit after tax Rs m10,604784 1,353.3%  
Gross profit margin %35.6-1.1 -3,209.9%  
Effective tax rate %24.050.3 47.8%   
Net profit margin %26.113.9 187.8%  
BALANCE SHEET DATA
Current assets Rs m40,1059,522 421.2%   
Current liabilities Rs m6,5953,296 200.1%   
Net working cap to sales %82.5110.4 74.7%  
Current ratio x6.12.9 210.5%  
Inventory Days Days11937 323.8%  
Debtors Days Days8128 283.9%  
Net fixed assets Rs m19,99546 43,467.4%   
Share capital Rs m531123 430.2%   
"Free" reserves Rs m53,0437,213 735.4%   
Net worth Rs m53,5747,336 730.2%   
Long term debt Rs m00-   
Total assets Rs m61,58511,105 554.6%  
Interest coverage x618.429.5 2,097.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.5 130.0%   
Return on assets %17.37.6 228.4%  
Return on equity %19.810.7 185.3%  
Return on capital %26.122.2 117.4%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38461 58,389.2%   
Fx outflow Rs m10,3993,630 286.4%   
Net fx Rs m24,985-3,570 -699.9%   
CASH FLOW
From Operations Rs m11,4931,610 713.9%  
From Investments Rs m-11,372687 -1,655.3%  
From Financial Activity Rs m-93-2,677 3.5%  
Net Cashflow Rs m28-380 -7.5%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 2.0 590.0%  
FIIs % 19.0 1.6 1,187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.5 80.0%  
Shareholders   31,796 41,647 76.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 17, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS